

January 29, 2018

Company name: RIBOMIC Inc.
Stock code: 4591
Listing: TSE, Mothers Market
URL: <http://www.ribomic.com/en/>

We held a pre-IND meeting with the U.S. FDA for clinical trials of age-related macular degeneration.

We are planning a clinical trial in the United States for age-related macular degeneration with in-house developed agent, RBM-007 (anti-FGF2 aptamer).

We are pleased to inform you that the pre-IND Meeting for the clinical trial application (Investigational New Drug Application, IND application) was held with the U.S. Food and Drug Administration (Food and Drug Administration), the regulatory authority, on January 26 (January 25, local).

The purpose of this meeting is to facilitate formal IND submissions by consulting beforehand about concerns about the investigational products and clinical trials, as well as the clinical trial plans. We had a face-to-face meeting with FDA's ophthalmology department (Division of Transplant and Ophthalmology Products) at the FDA office in Silver Spring, Maryland, USA. (4 members including the President and CEO from the Ribomic Head Office, the CEO from RIBOMIC USA Inc and three specialist advisors including Dr. Robert B.Bhisitkul, a scientific advisor at the University of California, San Francisco Medical Center, U.S.A.)

At this meeting, FDA did not point out any particular issues on the various data and clinical trial plan in the pre-IND Briefing Package provided by Ribomic and provided us valuable comments and suggestions for clinical trial plan.

Based on this discussion with FDA, we plan to file an IND application for wet AMD in the first quarter of FY2018, in view of the timing of the manufacture of the investigational product, and we will make preparations for the commencement of clinical trials.

The first patient enrollment in a clinical trial is anticipated to be around the summer of 2018.

Profile of RIBOMIC

RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is a type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug development platform, can be used for the development of many types of aptamer drugs. RIBOMIC is dedicated to the discovery of drugs that target the broad field of unmet medical needs, which encompasses pain, eye disorders, fibrosis and many other problems.

【Inquiries:Corporate Planning Department +81-3-3440-3745】